Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Molecular Biology Reports|October 11, 2017
The c.29T>C polymorphism of the transforming growth factor beta-1 (TGFB1) gene, bone mineral density and the occurrence of low-energy fractures in patients with inflammatory bowel diseaseI Krela-Kaźmierczak, M Michalak, A Wawrzyniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsMichael V Seiden, Shu-Wing Ng, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumorsDavid P Ryan, Joseph P Eder, Thomas Puchlaski, et al.
Investigational New Drugs|January 24, 2004
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignanciesJoseph P Eder, Rocio Garcia-Carbonero, Jeffrey W Clark, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2005
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsJoseph P Eder, David P Ryan, Leonard Appleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumorsLinda L Garland, Manuel Hidalgo, David S Mendelson, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Molecular Biology Reports|October 11, 2017
The c.29T>C polymorphism of the transforming growth factor beta-1 (TGFB1) gene, bone mineral density and the occurrence of low-energy fractures in patients with inflammatory bowel diseaseI Krela-Kaźmierczak, M Michalak, A Wawrzyniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumorsMichael V Seiden, Shu-Wing Ng, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.
Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.
British Journal of Cancer|June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumorsDavid P Ryan, Joseph P Eder, Thomas Puchlaski, et al.
Investigational New Drugs|January 24, 2004
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignanciesJoseph P Eder, Rocio Garcia-Carbonero, Jeffrey W Clark, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2005
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsJoseph P Eder, David P Ryan, Leonard Appleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumorsLinda L Garland, Manuel Hidalgo, David S Mendelson, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Pageof 12